As people age, their immune systems become weaker, and they become more vulnerable to infectious diseases. Preventing these infections through a proper vaccination strategy is essential for promoting healthy ageing. The VITAL project will map the burden of vaccine-preventable infectious diseases in the elderly, and investigate vaccinations and immunity to infections in the ageing population. The team will also calculate the clinical and economic consequences of possible vaccination strategies in different age and risk groups, and develop educational materials for stakeholders such as healthcare providers. Ultimately, by addressing the challenge of infectious diseases in the elderly, the VITAL project will contribute to better health for the ageing populations, and a reduced burden on healthcare systems.
VITAL
Vaccines and infectious diseases in the ageing population
FACTS & FIGURES
| Start Date |
|
| End Date |
|
| Call |
IMI2 - Call 12
|
| Grant agreement number |
806776
|
Type of Action:
RIA (Research and Innovation Action)
| Contributions | € |
|---|---|
| IMI Funding |
5 499 882
|
| EFPIA in kind |
6 927 335
|
| Total Cost |
12 427 218
|
Summary
Participants Show participants on map
EFPIA companies
- Biomerieux SA, Marcy L'Etoile, France
- Federation Europeenne D'Associations Et D'Industries Pharmaceutiques, Brussels, Belgium
- Glaxosmithkline Biologicals SA, Rixensart, Belgium
- Janssen Vaccines & Prevention BV, Leiden, Netherlands
- Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States
- Pfizer Limited, Sandwich, Kent , United Kingdom
- Sanofi Pasteur SA, Lyon, France
Universities, research organisations, public bodies, non-profit groups
- Academisch Ziekenhuis Groningen, Groningen, Netherlands
- Centre National De La Recherche Scientifique Cnrs, Paris, France
- Folkehelseinstituttet, Oslo, Norway
- Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain
- Imperial College Of Science Technology And Medicine, London, United Kingdom
- Institut National De La Sante Et De La Recherche Medicale, Paris, France
- Istituto Superiore Di Sanita, Roma, Italy
- Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
- Statens Serum Institut, Copenhagen S, Denmark
- Universita Degli Studi Di Ferrara, Ferrara, Italy
- Universitaet Innsbruck, Innsbruck, Austria
- Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
- Universite Jean Monnet Saint-Etienne, Saint Etienne Cedex 2, France
- University College London, London, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Mihajlovic Jovan, Novi Sad, Serbia
- P95 CVBA, Leuven, Belgium
- Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag, Budapest, Hungary
| Participants | |
|---|---|
| Name | IMI funding in € |
| Academisch Ziekenhuis Groningen | 363 750 |
| Centre National De La Recherche Scientifique Cnrs | 12 500 |
| Folkehelseinstituttet | 348 473 |
| Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana | 291 424 |
| Imperial College Of Science Technology And Medicine | 12 500 |
| Institut National De La Sante Et De La Recherche Medicale | 230 000 |
| Istituto Superiore Di Sanita | 90 603 |
| Mihajlovic Jovan | 60 000 |
| P95 CVBA | 186 375 |
| Rijksinstituut Voor Volksgezondheid En Milieu | 1 977 721 |
| Statens Serum Institut | 206 936 |
| Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag | 230 976 |
| Universita Degli Studi Di Ferrara | 230 625 |
| Universitaet Innsbruck | 263 750 |
| Universitair Medisch Centrum Utrecht | 781 750 |
| Universite Jean Monnet Saint-Etienne | 200 000 |
| University College London | 12 500 |
| Total Cost | 5 499 883 |
Project coordinator
Debbie Van Baarle
Universitair Medisch Centrum Utrecht
Debbie Van Baarle
Universitair Medisch Centrum Utrecht
LINKS AND DOCUMENTS
Project website
vital-imi.eu
Twitter
@VITAL_Europe